Susquehanna International Group’s Actuate Therapeutics ACTU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$43.1K Buy
+28,182
New +$65.3K ﹤0.01% 12880
2026
Q1
– Sell
-10,253
Closed -$62.7K – 14350
2025
Q4
$62.7K Buy
+10,253
New +$70.4K ﹤0.01% 11674
2025
Q2
– Sell
-47,634
Closed -$322K – 13929
2025
Q1
$322K Buy
+47,634
New +$382K ﹤0.01% 9908

Other funds holding ACTU

Susquehanna International Group's ACTU Position: Q2 2026 in Review

Susquehanna International Group opened a new position in Actuate Therapeutics (ACTU) in Q2 2026: 28,182 shares worth $43.1K. The stake represents ﹤0.01% of the portfolio and ranks #12880 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in ACTU as recently as Q4 2025.

Susquehanna International Group first reported a position in ACTU in Q1 2025 and has held it in 3 quarters since. The position peaked at $322K in Q1 2025. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Susquehanna International Group held 28,182 shares of Actuate Therapeutics worth $43.1K as of Q2 2026.
  • Actuate Therapeutics was a new Susquehanna International Group position in Q2 2026.
  • Actuate Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #12880 holding.
  • Susquehanna International Group first reported a position in Actuate Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Susquehanna International Group's Actuate Therapeutics position peaked at $322K in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.